title: Therapeutic use of interferon-alpha for lymphomatoid papulosis.
abstract: BACKGROUND
  Lymphomatoid papulosis is a primary cutaneous, CD30 positive lymphoproliferative disorder with the potential to transform into systemic, malignant lymphoma. Therapeutic strategies for patients with lymphomatoid papulosis have been designed to prevent transformation but have proved to be either inefficacious or limited by side effects.
  
  
  METHODS
  The authors compared the clinical, histologic, and immunohistochemical features from a group of five patients receiving interferon-alpha (IFN-alpha) subcutaneously three times per week with the same features from a group of six patients receiving conventional therapy, including photochemotherapy, antibiotics, topical corticosteroids, or surgery, in an open trial.
  
  
  RESULTS
  In the IFN-alpha group, four patients showed a complete remission, and one patient showed a partial remission within a time period of 6 weeks. Two patients developed disease recurrences after discontinuation of short term IFN-alpha therapy (5-7 months). Thereof, one patient went into stable remission after long term IFN-alpha therapy (17 months), and one patient remains in partial remission. In the control group, one patient went into spontaneous remission, two patients showed partial remission, of which one patient developed progressive disease at a later time point, whereas three patients have recurrent disease despite of treatment.
  
  
  CONCLUSIONS
  The current results indicate that the treatment with IFN-alpha of patients with lymphomatoid papulosis alters the clinical course of the disease with fewer side effects than previous regimens; however, short term treatment does not induce stable remission. Therefore, prolonged treatment appears to be warranted for these patients.
authors.affiliation: Department of Dermatology, University of Innsbruck, Innsbruck, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Schmuth
authors.forename: G
authors.initials: G
authors.lastname: Topar
authors.forename: B
authors.initials: B
authors.lastname: Illersperger
authors.forename: E
authors.initials: E
authors.lastname: Kowald
authors.forename: P O
authors.initials: PO
authors.lastname: Fritsch
authors.forename: N T
authors.initials: NT
authors.lastname: Sepp
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D017731:Lymphomatoid Papulosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010789:Phototherapy; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D016898:Interferon-alpha